A Comparison of IHC and FISH Cytogenetic Methods in the Evaluation of HER2 Status in Breast Cancer

被引:32
作者
Wesola, Marta [1 ]
Jelen, Michal [1 ]
机构
[1] Wroclaw Med Univ, Dept Pathomorphol & Oncol Cytol, PL-50556 Wroclaw, Poland
来源
ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE | 2015年 / 24卷 / 05期
关键词
breast cancer; immunohistochemistry; HER-2/neu; fluorescence in situ hybridization; IN-SITU HYBRIDIZATION; HER-2/NEU PROTEIN OVEREXPRESSION; GENE AMPLIFICATION; INTEROBSERVER REPRODUCIBILITY; IMMUNOHISTOCHEMISTRY; CARCINOMA; ONCOGENE; TRASTUZUMAB; ASSOCIATION; SURVIVAL;
D O I
10.17219/acem/27923
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The HER2 gene is responsible for the formation of the HER2 receptor on the surface of epithelial cells. Increased numbers of this receptor are associated with a worse prognosis in cancer. Increased numbers of copies of the HER2 gene occur in about 20-30% of breast cancer patients, so determining HER2 receptor levels is important in the current diagnosis and treatment of breast cancer. One diagnostic technique is the immunohistochemical (IHC) method, which permits indirect measurement of overexpression of HER2 receptors, based on subjective determination of the intensity of the color reaction. Another technique is the use of fluorescent in situ hybridization (FISH), which permits the exact number of copies of the HER2 gene to be specified. Based on the results of FISH tests, patients can be qualified for treatment with antibodies that partially block HER2 receptors. This treatment causes inhibition of tumor growth signals. Determining the HER2 status in breast cancer with the FISH method allows the further progress of the disease to be predicted, the right treatment to be chosen and the response to the treatment to be foreseen. Because of the widespread use of the FISH and IHC methods, comparing the advantages and disadvantages of these two methods seems to be relevant
引用
收藏
页码:899 / 903
页数:5
相关论文
共 40 条
[1]   Comparison of fluorescent in situ hybridization HER-2/neu results on core needle biopsy and excisional biopsy in primary breast cancer [J].
Apple, Sophia K. ;
Lowe, Alarice C. ;
Rao, P. Nagesh ;
Shintaku, I. Peter ;
Moatamed, Neda A. .
MODERN PATHOLOGY, 2009, 22 (09) :1151-1159
[2]   Immunohistochemiluminescence detection: A quantitative tool in breast cancer HER-2 status evaluation [J].
Barreto de Melo Rego, Moacyr Jesus ;
Cordeiro, Marina Ferraz ;
Bezerra Cavalcanti, Carmelita de Lima ;
de Carvalho Junior, Luiz Bezerra ;
Carneiro Beltrao, Eduardo Isidoro .
DISEASE MARKERS, 2013, 34 (05) :373-377
[3]   HER-2/neu detection in fine-needle aspirates of breast cancer - Fluorescence in situ hybridization and immunocytochemical analysis [J].
Beatty, BG ;
Bryant, R ;
Wang, WC ;
Ashikaga, T ;
Gibson, PC ;
Leiman, G ;
Weaver, DL .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2004, 122 (02) :246-255
[4]  
Belengeanu A, 2010, ROM J MORPHOL EMBRYO, V51, P321
[5]   The association of HER-2/neu amplification with breast cancer recurrence [J].
Carr, JA ;
Havstad, S ;
Zarbo, RJ ;
Divine, G ;
Mackowiak, P ;
Velanovich, V .
ARCHIVES OF SURGERY, 2000, 135 (12) :1469-1474
[6]  
Chariyalertsak S, 2011, ASIAN PAC J CANCER P, V12, P1703
[7]   Comparison of immunohistochemical and fluorescence in situ hybridization assessment of HER-2 status in routine practice [J].
Dolan, M ;
Snover, D .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2005, 123 (05) :766-770
[8]   Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab [J].
Dybdal, N ;
Leiberman, G ;
Anderson, S ;
McCune, B ;
Bajamonde, A ;
Cohen, RL ;
Mass, RD ;
Sanders, C ;
Press, MF .
BREAST CANCER RESEARCH AND TREATMENT, 2005, 93 (01) :3-11
[9]   Chemiluminescence Platforms in Immunoassay and DNA Analyses [J].
Fan, Aiping ;
Cao, Zhijuan ;
Li, Huan ;
Kai, Masaaki ;
Lu, Jianzhong .
ANALYTICAL SCIENCES, 2009, 25 (05) :587-597
[10]  
Goud KI, 2012, INDIAN J MED RES, V135, P312